ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

July 1, 2026

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

Harvard

Cambridge, MA
Key Differentiators
- Oncology
#3

Weill Cornell Medical College

New York, NY
Key Differentiators
- Oncology
#4

Cleveland Clinic Lerner College of Medicine

Cleveland, OH
Key Differentiators
- Oncology
#5

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology